Adverts

Open Access Articles- Top Results for Brivaracetam

Brivaracetam

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. colspan=2 class="borderless" border=0 align=center #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.
Brivaracetam

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Names

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

IUPAC name
(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Identifiers#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-




ChEMBL ChEMBL607400 7pxY ChemSpider 8012964 7pxY Jmol-3D images Image PubChem Template:Chembox PubChem/format Template:Chembox UNII colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Properties

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

C11H20N2O2 Molar mass Lua error in Module:Math at line 495: attempt to index field 'ParserFunctions' (a nil value). g·mol−1 colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Pharmacology

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


Bioavailability Nearly 100% Oral Metabolism Hydrolysis, CYP2C8-mediated hydroxylation 8 hrs Protein binding <20% Excretion >75% renal Legal status
  • Investigational
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 14pxY verify (what is10pxY/10pxN?) Infobox references

Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties.[1][2] Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A).[3] Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded,[4][5] along with evidence that it is around 10 times more potent[6] for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.

References

  1. ^ von Rosenstiel P (Jan 2007). "Brivaracetam (UCB 34714)". Neurotherapeutics 4 (1): 84–7. PMID 17199019. doi:10.1016/j.nurt.2006.11.004. 
  2. ^ Malawska B, Kulig K (Jul 2005). "Brivaracetam UCB". Current Opinion in Investigational Drugs 6 (7): 740–746. PMID 16044671. 
  3. ^ Rogawski MA, Bazil CW (Jul 2008). "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports 8 (4): 345–352. PMC 2587091. PMID 18590620. doi:10.1007/s11910-008-0053-7. 
  4. ^ Clinical trial number NCT00464269 for "Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures" at ClinicalTrials.gov
  5. ^ Rogawski MA (Aug 2008). "Brivaracetam: a rational drug discovery success story". British Journal of Pharmacology 154 (8): 1555–7. PMC 2518467. PMID 18552880. doi:10.1038/bjp.2008.221. 
  6. ^ Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H (Aug 2008). "Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A". British Journal of Pharmacology 154 (8): 1662. PMID 18500360. doi:10.1038/bjp.2008.198. 


Lua error in package.lua at line 80: module 'Module:Buffer' not found.